AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 127.58 Increased By ▲ 0.54 (0.43%)
BOP 6.64 Decreased By ▼ -0.03 (-0.45%)
CNERGY 4.60 Increased By ▲ 0.09 (2%)
DCL 8.43 Decreased By ▼ -0.12 (-1.4%)
DFML 41.50 Increased By ▲ 0.06 (0.14%)
DGKC 86.70 Decreased By ▼ -0.15 (-0.17%)
FCCL 32.20 Decreased By ▼ -0.08 (-0.25%)
FFBL 65.48 Increased By ▲ 0.68 (1.05%)
FFL 10.25 No Change ▼ 0.00 (0%)
HUBC 110.80 Increased By ▲ 1.23 (1.12%)
HUMNL 14.97 Increased By ▲ 0.29 (1.98%)
KEL 5.18 Increased By ▲ 0.13 (2.57%)
KOSM 7.12 Decreased By ▼ -0.34 (-4.56%)
MLCF 41.25 Decreased By ▼ -0.13 (-0.31%)
NBP 60.24 Decreased By ▼ -0.17 (-0.28%)
OGDC 193.65 Increased By ▲ 3.55 (1.87%)
PAEL 28.00 Increased By ▲ 0.17 (0.61%)
PIBTL 7.97 Increased By ▲ 0.14 (1.79%)
PPL 151.00 Increased By ▲ 0.94 (0.63%)
PRL 27.14 Increased By ▲ 0.26 (0.97%)
PTC 16.30 Increased By ▲ 0.23 (1.43%)
SEARL 78.37 Decreased By ▼ -7.63 (-8.87%)
TELE 7.45 Decreased By ▼ -0.26 (-3.37%)
TOMCL 35.67 Increased By ▲ 0.26 (0.73%)
TPLP 7.91 Decreased By ▼ -0.21 (-2.59%)
TREET 16.00 Decreased By ▼ -0.41 (-2.5%)
TRG 53.18 Decreased By ▼ -0.11 (-0.21%)
UNITY 26.75 Increased By ▲ 0.59 (2.26%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
BR100 9,884 No Change 0 (0%)
BR30 30,600 No Change 0 (0%)
KSE100 93,943 Increased By 587.9 (0.63%)
KSE30 29,119 Increased By 188.2 (0.65%)

The Federal Health Ministry, after a gap of 7 years, granted permission to local pharmaceutical companies to make an upward revision in the prices from 7 to 20 percent on 240 locally manufactured drugs. The increase came into affect after persistence appeal by the Pakistan Pharmaceutical Manufacturers Association (PPMA).
An official of the PPMA informed that increase in rates of 240 locally manufactured medicines out of total 47,000 produced in the country was necessary, as their cost of manufacturing had exceeded, prices making it virtually impossible for the related pharmaceutical companies to produce them. As a result, shortage of these medicines caused immense hardship for a large number of patients.
Federal Secretary Health and DG Health also attended the meeting besides other high officials of the health department. Members of the delegation informed the minister about static rates of medicines during the last 7 years despite steep rise in inflation, devaluation of the Pakistani rupee and increase in the input price of the pharmaceutical sector, which forced the industry to face worst ever crises.
Massive increase in raw and packaging material rates, majority of which was imported from abroad for catering to the requirement of indigenous industry was also brought to the notice of the minister.
However, despite presentation of all facts and figures, response of the Federal Minister was unfavourable as he failed to give patient hearing to the problems faced by the pharmaceutical industry in the country. He told them plainly that the government would not hesitate importing medicines from India if the local pharmaceutical industry shuts down their businesses.

Copyright Business Recorder, 2008

Comments

Comments are closed.